ENT Cancer Clinical Trial
Official title:
Randomized, Double Blind, Efficacy Study of Escitalopram Versus Placebo in ENT Cancer Patients Suffering From Emotional Distress
Escitalopram is an antidepressant inhibitor of the serotonin reuptake. On the market in
France since 2002.
Prevalence of emotional distress in patients with cancer is 30-50%. this prevalence may vary
regarding the tumor localisation, the population, intensity of the symptoms...
Incidence of ENT cancer is highly significant in France, it is one of the most important in
the world 37 out of 100 000. it is in patients with ENT cancer that the prevalence of
depression is the most important (22%-57%).
Researches appears necessary to assessed the efficacy of antidepressant treatments with as
primary objective not only the decrease of depressive symptoms but also an ensemble of
physic and psychological symptoms.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|